Editorial methodology

Last reviewed April 24, 2026.

PeptideHelper.org is an editorial reference compiled from primary regulatory sources, peer-reviewed literature, and practitioner-oriented peptide guides. This page documents how the data is sourced, weighted, reviewed, and corrected — the discipline that turns a list of compounds into a trustworthy reference.

Data sources

Every peptide entry traces to one or more of the following primary sources:

• Regulatory — FDA drug labels (DailyMed and Drugs@FDA), FDA Drug Safety Communications, the FDA 503A and 503B bulks lists, and EMA assessment reports.
• Clinical trials — ClinicalTrials.gov registrations and the peer-reviewed publications of those trials in indexed journals (NEJM, Lancet, JAMA, Nature Medicine, Diabetes Care, Endocrine Reviews, et al.).
• Mechanistic literature — peer-reviewed pharmacology, biochemistry, and structural-biology papers indexed on PubMed; preference is given to published reviews over single-lab primary papers when available.

Non-peer-reviewed material (industry blogs, vendor catalogs, lay-press health sites) is not a primary source on this site. Where a published review or regulatory document does not yet exist for a given claim, the entry says so explicitly in the Evidence tier or omits the claim entirely.

Evidence tiers

The "Evidence" badge on every peptide reflects a four-tier rubric:

FDA-Approved

Has a current FDA-approved indication and active label.

Phase 3 / Phase 2

Active or completed late-stage human trials registered on ClinicalTrials.gov with published readouts.

Anecdotal + Animal Studies

Animal data and/or open-label small-N human use; no controlled human trials.

Preclinical only

In-vitro or animal data only; no published human use.

How conflict rules are constructed

The Evaluator uses three rule families:

• Class conflicts — two or more peptides sharing a pharmacologic class (two GHRHs, two GLP-1 agonists) trigger a conflict regardless of whether a specific pair is enumerated.
• Pair rules — specific peptide-plus-anything-else combinations drawn from documented contraindications.
• Toggle rules — concomitant medications (insulin/secretagogues, exogenous HGH) layer in additional warnings.

Every rule has a why field traceable to a published source. Rules without traceable sourcing are not added.

Review cadence

The site is reviewed end-to-end every quarter:

• Regulatory status refreshed against the current FDA Compounding lists and 503A bulk-drug list.
• New trial readouts checked against ClinicalTrials.gov for any peptide in the catalog.
• Conflict-rule registry checked against any new contraindication communications.
• Footer "Last reviewed" stamp and per-page review dates updated.

Out-of-cycle updates are issued for FDA recalls, black-box additions, or major Phase 3 readouts.

Editorial team

Editor: Connor Finuf — site author and data curator.
Medical reviewer: Position open. The site is actively recruiting a licensed MD, PharmD, or PhD pharmacology reviewer for named editorial review of every peptide entry. This page will be updated with the reviewer's name, credentials, and review scope when that role is filled.

Conflicts of interest

Some outbound links on this site are affiliate links. The presence or absence of a vendor link has no influence on whether a peptide is included or how it is ranked. Inclusion criteria are: clinical relevance, mechanistic coverage of the catalog, and presence in the peer-reviewed literature. Affiliate programs are disclosed in full on the Affiliate Disclosure page.

Reader corrections

If you spot a factual error, a stale regulatory note, or a missing source, email corrections@peptidehelper.org. Corrections are logged and surfaced in the next quarterly review with the contributor credited (unless they request anonymity).

Catalog scope

The current snapshot covers 103 peptides, 8 validated stacks, and 6 contraindicated combinations. The catalog grows on the quarterly review schedule as new compounds enter clinical literature or as reader requests are validated.